

Björn Henning Grönberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/356100/publications.pdf>

Version: 2024-02-01

16
papers

605
citations

1039406

9
h-index

996533

15
g-index

16
all docs

16
docs citations

16
times ranked

897
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3217-3224.	0.8	266
2	Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. <i>European Journal of Cancer</i> , 2010, 46, 2225-2234.	1.3	112
3	Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. <i>Acta Oncologica</i> , 2016, 55, 591-597.	0.8	69
4	Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway. <i>Acta Oncologica</i> , 2015, 54, 395-402.	0.8	39
5	Comparing comorbidity scales: Attending physician score versus the Cumulative Illness Rating Scale for Geriatrics. <i>Journal of Geriatric Oncology</i> , 2016, 7, 90-98.	0.5	23
6	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. <i>Lung Cancer</i> , 2012, 78, 63-69.	0.9	22
7	A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer. <i>European Journal of Clinical Nutrition</i> , 2019, 73, 1069-1076.	1.3	19
8	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. <i>Acta Oncologica</i> , 2017, 56, 1776-1785.	0.8	17
9	The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. <i>Cancers</i> , 2021, 13, 4294.	1.7	10
10	Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 1283-1290.	2.9	9
11	Geriatric impairments are prevalent and predictive of survival in older patients with cancer receiving radiotherapy: a prospective observational study. <i>Acta Oncologica</i> , 2022, 61, 393-402.	0.8	8
12	Associations between severe comorbidity and muscle measures in advanced non-small cell lung cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1347-1355.	2.9	4
13	Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials. <i>Acta Oncologica</i> , 2018, 57, 1574-1579.	0.8	3
14	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta Oncologica</i> , 2021, 60, 1565-1571.	0.8	2
15	Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC. <i>Healthcare (Switzerland)</i> , 2022, 10, 922.	1.0	2
16	Changes in muscle measures during chemoradiotherapy in patients with limited stage small cell lung cancer. <i>JCSM Clinical Reports</i> , 2021, 6, 24-32.	0.5	0